704 related articles for article (PubMed ID: 29327061)
1. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Oshima Y; Tanimoto T; Yuji K; Tojo A
JAMA Oncol; 2018 Aug; 4(8):1112-1115. PubMed ID: 29327061
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
[TBL] [Abstract][Full Text] [Related]
3. Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in
Girard N; Moro-Sibilot D; Bouée S; Emery C; Torreton E; Le Lay K; Luciani L; Maritaz C; Chouaid C
Future Oncol; 2020 Jun; 16(16):1115-1124. PubMed ID: 32352321
[No Abstract] [Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
Ito K; Murotani K; Kubo A; Kunii E; Taniguchi H; Shindoh J; Asada K; Imaizumi K; Takahashi K; Karayama M; Okuno M; Inui N; Hataji O; Morikawa S; Hayai S; Suda T; Abe T; Tsuda T; Yamagichi T; Kimura T; Oya Y; Yoshida T; Hida T
Cancer Sci; 2020 Oct; 111(10):3705-3713. PubMed ID: 32639668
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
7. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Su VY; Yang KY; Huang TY; Hsu CC; Chen YM; Yen JC; Chou YC; Chang YL; He CH
Sci Rep; 2020 Sep; 10(1):14965. PubMed ID: 32917914
[TBL] [Abstract][Full Text] [Related]
9. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N; Ichihara E; Tanaka T; Ninomiya T; Kozuki T; Ishikawa N; Nishii K; Shoda H; Yamaguchi K; Kawakado K; Toyoda Y; Inoue M; Miyatake N; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kojima K; Kadowaki N
Lung; 2024 Feb; 202(1):63-72. PubMed ID: 38265672
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
[TBL] [Abstract][Full Text] [Related]
12. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
13. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915
[TBL] [Abstract][Full Text] [Related]
14. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O; Kaira K; Kawasaki T; Mouri A; Hashimoto K; Shiono A; Shinomiya S; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Mochida S; Kagamu H
Thorac Cancer; 2020 Apr; 11(4):1045-1051. PubMed ID: 32068351
[TBL] [Abstract][Full Text] [Related]
15. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
[TBL] [Abstract][Full Text] [Related]
16. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
17. Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study.
Ma Z; Pei J; Zhang Y; Li H; Sun D; Zhang Y; An Z
Expert Opin Drug Saf; 2023 Mar; 22(3):237-242. PubMed ID: 35924402
[TBL] [Abstract][Full Text] [Related]
18. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
19. EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?
Mormile R
Pathol Oncol Res; 2019 Oct; 25(4):1665-1666. PubMed ID: 30661223
[No Abstract] [Full Text] [Related]
20. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y
Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
